Branch retinal vein occlusion treated with anti-VEGF: to switch or not to switch?
- 22 February 2024
- journal article
- research article
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (6) , e824-e829
Abstract
No abstract availableKeywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysisBMJ Open, 2015
- A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1British Journal of Ophthalmology, 2015
- PROGRESSIVE RETINAL NONPERFUSION IN ISCHEMIC CENTRAL RETINAL VEIN OCCLUSIONRetina, 2015
- Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with RanibizumabOphthalmology, 2014
- BRANCH RETINAL VEIN OCCLUSIONRetina, 2013
- Statistical guidelines for the analysis of data obtained from one or both eyesOphthalmic and Physiological Optics, 2012
- Ranibizumab for Macular Edema Due to Retinal Vein OcclusionsOphthalmology, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and AustraliaOphthalmology, 2010
- Argon Laser Photocoagulation for Macular Edema in Branch Vein OcclusionAmerican Journal of Ophthalmology, 1984